Reference #18.2733ca17.1648075426.1e065090
Dual Immunotherapy Improves PFS In Melanoma Resistant To Anti-PD-1
NEW ORLEANS -- Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved outcomes compared with ipilimumab alone for patients with advanced melanoma who have primary resistance to PD-1 inhibitors, a randomized study found. While median progression-free survival (PFS) was similar between the two arms of the trial, at 3 months and 2.7 months,...